This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Hybrid or Mixed Marketing Authorization Application in the EU: not a trivial decision in new development programs for established drugs
Published on: Feb 20, 2012
For any medicinal product Marketing Authorization Application (MAA) in the European Union, the applicant needs to indicate the legal basis for the application. This legal basis, laid down in Directive 2001/83/EC as amended, determines the dossier content, the market exclusivity, and the pediatric requirements in a significant way.
Andreas Vogel
Hybrid or Mixed Marketing Authorization Application in the EU: not a trivial decision in new development programs for established drugs
2012 – Drug Information Journal